Advertisement

Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or Apremilast

  • Nicola E. NatsisEmail author
  • Joseph F. Merola
  • Jeffrey M. Weinberg
  • Jashin J. Wu
  • Ana-Maria Orbai
  • Jerry Bagel
  • Alice B. Gottlieb
Therapy in Practice

Abstract

Elderly patients are a group with a high frequency of psoriasis. Their disease burden has negative impacts on their quality of life. While there is a clear need to treat these patients, there are challenges in doing so. This work seeks to define the challenges that exist in treating elderly Medicare patients, as well as to provide treatment suggestions for providers to follow if they encounter one or more of these challenges. Providers face the following challenges when creating treatment plants for elderly patients with psoriasis: difficulty in obtaining drug coverage through Medicare, increased medical comorbidities, and polypharmacy. Providers aim for regimens that are affordable, safe, and efficacious, but it is not always clear how to achieve this combination, especially in elderly Medicare patients. This work is relevant in that it aims to explain the logistical roadblocks posed by Medicare coverage and provide solutions for commonly encountered issues in the treatment of a disabling and common disease in a high-risk population. Specifically, alternative treatment options to biologics and small-molecule inhibitors are discussed and include topical therapies, phototherapy, methotrexate, acitretin, and cyclosporine and for psoriatic arthritis include corticosteroids and leflunomide. The specific risks and benefits of these therapies in the elderly population are provided, allowing providers to make patient-specific decisions about optimal regimens.

Notes

Acknowledgements

The authors acknowledge Stacie Bell at the National Psoriasis Foundation for her support of this manuscript.

Compliance with Ethical Standards

Funding

This project was not funded, and there are no conflicts of interest related to this project.

Conflict of interest

Author disclosures are provided below for full transparency, although none of the authors were compensated for this project. Nicola E. Natsis has been previously hired as a scientific writer for XBiotech USA for unrelated projects. Joseph F. Merola is a consultant and/or investigator for Merck Research Laboratories, Abbvie, Dermavant, Eli Lilly and Company, Novartis, Janssen, UCB, Samumed, Celgene, Sanofi Regeneron, GSK, Almirall, Sun Pharma, Biogen, Pfizer, Incyte, Aclaris, and Leo Pharma. Jeffrey M. Weinberg is an investigator for AbbVie, Amgen, Celgene, Eli Lilly, UCB, BMS, and Novartis and a speaker for AbbVie, Celgene, Novartis, Regeneron, Sun Pharmaceutical, UCB, and Valeant Pharmaceuticals North America LLC. Jashin J. Wu is an investigator for AbbVie, Amgen, Eli Lilly, Janssen, and Novartis; a consultant for AbbVie, Almirall, Amgen, Bristol-Myers Squibb, Celgene, Dermira, Dr. Reddy’s Laboratories, Eli Lilly, Janssen, LEO Pharma, Novartis, Promius Pharma, Regeneron, Sun Pharmaceutical, UCB, and Valeant Pharmaceuticals North America LLC; and a speaker for AbbVie, Celgene, Novartis, Regeneron, Sun Pharmaceutical, UCB, and Valeant Pharmaceuticals North America LLC. Ana-Maria Orbai is a Jerome L. Greene Foundation Scholar and is supported in part by a research grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award number P30-AR070254 (Core B). Ana-Maria Orbai received research grants from Abbvie, Celgene, Eli Lilly, Horizon, Janssen, and Novartis and consulting fees from Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Jerry Bagel is a consultant, speaker, and/or investigator for Abbvie, Amgen, BI,BMS, Celgene, Jahnssen, Leo, Eli-Lilly, Novartis, and Ortho-Dermatologics. Alice B. Gottlieb is a consultant/advisory board/speaker bureau member of Janssen Inc., Celgene Corp., Beiersdorf, Bristol Myers Squibb Co., Abbvie, UCB, Novartis, Incyte, Lilly, Reddy Labs, Valeant, Dermira, Allergan, Sun Pharmaceuticals Industries, Xbiotech, Leo, Avotres Therapeutics, and Boeringer Ingelheim. She holds research/educational grants from Janssen, Incyte, Novartis, Xbiotech, UCB, and Boeringer Ingelheim.

References

  1. 1.
    MedPac. The next generation of Medicare beneficiaries. Report to the Congress: Medicare and the health care delivery system. 2015. http://www.medpac.gov/docs/default-source/reports/chapter-2-the-next-generation-of-medicare-beneficiaries-june-2015-report-.pdf?sfvrsn=0. Accessed 19 Aug 2019.
  2. 2.
    Park YJ, Martin EG. Medicare Part D’s effects on drug utilization and out-of-pocket costs: a systematic review. Health Serv Res. 2017;52(5):1685–728.CrossRefPubMedGoogle Scholar
  3. 3.
    Center for Medicare Advocacy. Assistance with paying for prescription drugs. 2015. http://www.medicareadvocacy.org/finding-help-to-get-prescription-drugs/. Accessed 19 Aug 2019.
  4. 4.
    Rankin A, Cadogan C, Patterson S, Kerse N, Cardwell C, Bradley M, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2018;9:CD008165.PubMedGoogle Scholar
  5. 5.
    Balato N, Patruno C, Napolitano M, Patrì A, Ayala F, Scarpa R. Managing moderate-to-severe psoriasis in the elderly. Drugs Aging. 2014;31(4):233–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Tveit KS, Duvetorp A, Østergaard M, Skov L, Danielsen K, Iversen L, et al. Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). J Eur Acad Dermatol Venereol. 2019;33(2):340–54.CrossRefPubMedGoogle Scholar
  7. 7.
    Juneja M, Baidoo L, Schwartz MB, Barrie A, Regueiro M, Dunn M, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57(9):2408–15.CrossRefPubMedGoogle Scholar
  8. 8.
    Morgacheva O, Furst DE. Use of methotrexate in the elderly and in patients with compromised renal function. Clin Exp Rheumatol. 2010;28(5 Suppl. 61):S85–94.PubMedGoogle Scholar
  9. 9.
    Medina C, Carretero G, Ferrandiz C, Dauden E, Vanaclocha F, Gómez-García FJ, et al. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry. J Eur Acad Dermatol Venereol. 2015;29(5):858–64.CrossRefPubMedGoogle Scholar
  10. 10.
    Piaserico S, Conti A, Console F, Simone C, Prestinari F, Mazzotta A, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2014;94(3):293–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Garber C, Plotnikova N, Au SC, Sorensen EP, Gottlieb A. Biologic and conventional systemic therapies show similar safety and efficacy in elderly and adult patients with moderate to severe psoriasis. J Drugs Dermatol. 2015;14(8):846–52.PubMedGoogle Scholar
  12. 12.
    Napolitano M, Balato N, Ayala F, Patruno C, Patrì A, Megna M, et al. Psoriasis in elderly and non-elderly population: clinical and molecular features. G Ital Dermatol Venereol. 2016;151(6):587–95.PubMedGoogle Scholar
  13. 13.
    Megna M, Napolitano M, Balato N, Monfrecola G, Villani A, Ayala F, et al. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol. 2016;41:564–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Körber A, Papavassilis C, Bhosekar V, Reinhardt M. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies. Drugs Aging. 2018;35(2):135–44.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Ricceri F, Bardazzi F, Chiricozzi A, Dapavo P, Ferrara F, Mugheddu C, et al. Elderly psoriatic patients under biological therapies: an Italian experience. J Eur Acad Dermatol. Venereol. 2019;33:143–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Cline A, Cardwell LA, Feldman SR. Advances in treating psoriasis in the elderly with small molecule inhibitors. Expert Opin Pharmacother. 2017;18(18):1965–73.CrossRefPubMedGoogle Scholar
  17. 17.
    Di Lernia V, Goldust M. An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly. Expert Opin Biol Ther. 2018;18(8):897–903.CrossRefPubMedGoogle Scholar
  18. 18.
    Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, et al. Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. J Cutan Med Surg. 2019;23(1):50–74.CrossRefPubMedGoogle Scholar
  19. 19.
    Sampogna F, Tabolli S, Mastroeni S, Di Pietro C, Fortes C, Abeni D. Quality of life impairment and psychological distress in elderly patients with psoriasis. Dermatology. 2007;215:341–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Yosipovitch G, Tang MBY. Practical management of psoriasis in the elderly. Drugs Aging. 2002;19(11):847–63.CrossRefPubMedGoogle Scholar
  21. 21.
    Dyer JM, Miller RA. Chronic skin fragility of aging: current concepts in the pathogenesis, recognition, and management of dermatoporosis. J Clin Aesthet Dermatol. 2018;11(1):13–8.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Mehta D, Lim HW. Ultraviolet B phototherapy for psoriasis: review of practical guidelines. Am J Clin Dermatol. 2016;17:125–33.CrossRefPubMedGoogle Scholar
  23. 23.
    Kim W, Shelley A, Novice K, Joo J, Lim H, Glassman S. Drug-induced phototoxicity: a systematic review. J Am Acad Dermatol. 2018;79(62):1069–75.CrossRefPubMedGoogle Scholar
  24. 24.
    Zhang P, Wu MX. A clinical review of phototherapy for psoriasis. Lasers Med Sci. 2017;33(1):173–80.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Bourre-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol. 2010;37(7):1416–21.CrossRefPubMedGoogle Scholar
  26. 26.
    Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, Brater DC. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol. 1992;42(2):121–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009;60(5):824–37.CrossRefPubMedGoogle Scholar
  28. 28.
    Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451–85.CrossRefPubMedGoogle Scholar
  29. 29.
    Fraunfelder FW, Fraunfelder FT. Evidence for a probable causal relationship between tretinoin, acitretin, and etretinate and intracranial hypertension. J Neuroophthalmol. 2004;3:214–6.CrossRefGoogle Scholar
  30. 30.
    Sarkar R, Chugh S, Garg VK. Acitretin in dermatology. Indian J Dermatol Venereol Leprol. 2013;79(6):759–71.CrossRefPubMedGoogle Scholar
  31. 31.
    Vahlquist C, Selinus I, Vessby B. Serum-lipid changes during acitretin (etretin) treatment of psoriasis and palmoplantar pustulosis. Acta Derm Venereol. 1988;68:300–5.PubMedGoogle Scholar
  32. 32.
    Ruzicka T, Sommerburg C, Braun-Falco O, Köster W, Lengen W, Lensing W, et al. Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol. 1990;126(4):482–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Potts GA, Hurley MY. Psoriasis in the geriatric population. Clin Geriatr Med. 2013;29(2):373–95.CrossRefPubMedGoogle Scholar
  34. 34.
    Butler DC, Koo JYM. Psoriasis therapy in the geriatric population. In: Chang ALS, editor. Advances in geriatric dermatology. New York: Springer; 2015. p. 65–9.CrossRefGoogle Scholar
  35. 35.
    Ohtsuki M, Nakagawa H, Sugai J, Ozawa A, Ohkido M, Nakayama J, et al. Long-term continuous versus intermittent cyclosporin: therapy for psoriasis. J Dermatol. 2003;30(4):290–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Scarpa R, Oriente P, Pucino A, Torella M, Vignone L, Riccio A, et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol. 1984;23:246–50.CrossRefPubMedGoogle Scholar
  37. 37.
    Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheumatol. 2004;50:1939–50.CrossRefGoogle Scholar
  38. 38.
    Ren Z, Chen S, Qing T, Xuan J, Couch L, Yu D, et al. Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 cells. Toxicology. 2017;392:11–21.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Alcorn N, Saunders S, Madhok R. Benefit-risk assessment of leflunomide. Drug Saf. 2009;32(12):1123–34.CrossRefPubMedGoogle Scholar
  40. 40.
    Bonnel RA, Graham DJ. Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther. 2004;75(6):580–5.CrossRefPubMedGoogle Scholar
  41. 41.
    Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40.CrossRefPubMedGoogle Scholar
  42. 42.
    Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.University of California San Diego School of MedicineLa JollaUSA
  2. 2.Harvard Medical SchoolBrigham and Women’s HospitalBostonUSA
  3. 3.Icahn School of Medicine at Mount SinaiNew YorkUSA
  4. 4.Dermatology Research and Education FoundationIrvineUSA
  5. 5.Division of RheumatologyJohns Hopkins University School of MedicineBaltimoreUSA
  6. 6.Psoriasis Treatment Center of Central New JerseyEast WindsorUSA
  7. 7.Department of DermatologyIcahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations